Sunday, June 1, 2014

HCV Weekend Reading; Behind evolving treatments for hepatitis C and progress toward a cure

Good afternoon folks, welcome to another edition of "Weekend Reading"

The sun is shinning bright in my part of the world, hope its doing the same where you live. Today, after updating the blog, Nana and the short people spent the afternoon running after flying fuzz, better known as (Santa Hair). We blew close to 32 pieces of fuzz back up to Santa.

If you get the time this weekend, after mowing the lawn, or spending time with family, take a look see at these updates.

First up is a NEJM podcast for those clinical savvy nerds; An Interview with Dr. Raymond Chung on the science behind evolving treatments for hepatitis C and progress toward a cure, if you missed the program its worth a listen.

In addition, two U.S. clinical trials sponsored by Janssen using Simeprevir in combination with Sofosbuvir for genotype 1 patients with or without Cirrhosis is now recruiting; Updated June 1 2014: Sofosbuvir Based Hepatitis C Clinical Trials.

Skim over the results from COSMOS, a study with Simeprevir and Sofosbuvir in cirrhotic and non-cirrhotic HCV genotype 1 patients presented at AASLD 2013, here, final phase II data presented at EASL 2014, here.  Read more about Sofosbuvir based regimes here, Gilead's Sofosbuvir and Ledipasvir fixed dose combination here,  Sovaldi (Sofosbuvir), here and bookmark this for later; Sofosbuvir in the Treatment of Hepatitis C-A Review of Its Clinical Potential.

In May Janssen Submitted a supplemental NDA to the U.S. FDA for OLYSIO™ (Simeprevir) in Combination with Sofosbuvir. 

Just updated on the website is a collection of research, news and health tips on viral hepatitis and liver health.

As we all know, the weekend wouldn't be complete without reading HCV Advocate's June Newsletter.

In This Issue:
HCV Drugs
Alan Franciscus, Editor-in-Chief

Lucinda K. Porter, RN

HEALTHWISE: Hepatitis C & Liver Cancer (HCC)
Lucinda K. Porter, RN

HCV Advocate Eblast
Stay informed on the latest
here to register for email alerts

Finally, on the blog is an index of current articles discussing the continuing controversy over the high price of Solvadi:
The coming epidemic..
A medical breakthrough actually worth paying for....
Why does Gilead's Sovaldi cost $84K in the U.S. and $57K in Britain?
At $1,000 per pill, new Hepatitis C drug has insurers and CCOs scratching their heads...
The Price is Right: New Hepatitis C Drug is Really a Priceless Breakthrough....
Check out the headlines here.....

Enjoy this lovely weekend, until next time.

Always Tina